I don't want to imply more than I know.
Money managers make decisions solely based on which stocks are good for their mutual funds. What usually calls a BB fund to their attention is a combination of sector, NASDAQ application, and performance. These are all tracked by computer programs that chart stocks and provide lists of those that may be researched manually, although many purchases are based on computer models only.
SNRS is a well performing BB find (today notwithstanding). Even conservative funds research stocks that are stabilizing in terms of daily fluctuation. When this movement is accompanied by lower than average volume, the stock recieves an attractive grade.
I only know of this model because a programmer who worked for me created this model for Smith Barney mutual funds and later for a consulting firm working with Insurance Company mutual funds.
Now for the Sunrise research part. Medical Directors at Healthcare companies are most often MD's (they probably all are) who determine wellness, preventive care priorities for their firms.
All companies that provide technology or drugs that could lower costs are researched, more so companies in the FDA live testing stages.
While I can't say specifically that SNRS was researched by the particular funds I mentioned, Medicare Directors at two of those firms were aware of LTK technology, in favor of the cost and the large treatment market, and in fact knew Sunrise by name.
This does not mean that money managers at the same companies would buy a stock just because the wellness area likes the price of the procedure, it just means that they share relevant data on the way to making their respective independent decisions.
If I implied that I knew these funds would buy the stock, I didn't mean to and I apologize. IMHO they will as soon as they can.
Rainer, what happened today or is the the "close to $10" you mentioned.
Regards to all,
Sylvester |
